首页 > 最新文献

Rare Tumors最新文献

英文 中文
Extraskeletal myxoid chondrosarcoma: A case series and review of the literature 骨外黏液样软骨肉瘤1例并文献复习
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221079754
Michael P. Fice, Linus Lee, Pavan Kottamasu, Abdullah Almajnooni, Matthew R. Cohn, Charles A. Gusho, S. Gitelis, Alan T. Blank
Background Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant soft tissue sarcoma (STS) that accounts for less than 3% of all soft tissue tumors. The conventional treatment for primary EMC is wide local excision with or without radiation therapy. Materials and Methods This study was a retrospective review of all EMC cases treated within a single institution between 1992 and 2019. EMC was diagnosed using a combination of histologic morphology and immunostaining, with confirmatory fluorescent in situ hybridization. Overall survival (OS) and disease-specific survival (DSS) were defined using Kaplan–Meier analysis. Results Fifteen patients were evaluated, including 11 males and four females. The average age at presentation was 51.7 ± 20.4 years and the mean follow-up time was 61.5 months (range, 5–286 months). The average resected tumor size at largest dimension was 7.14 cm (range, 2.4–18.7). Twelve of fifteen (80%) patients underwent wide local excision, and nine of the twelve (75%) underwent local radiation therapy. The 1-, 5-, and 10-year OS was 80% (95% CI, 59.8–100), 72% (95% CI, 48.5–95.5), and 72% (95% CI, 48.5–95.5), respectively. The 1-, 5-, and 10-year DSS was 92.3% (95% CI, 77.8–100), 83.1% (95% CI, 61.5–100), and 83.1% (95% CI, 61.5–100), respectively. At last follow-up, 11 patients were alive and ten (90.9%) were disease free. Conclusions Extraskeletal myxoid chondrosarcoma is a very rare STS most often seen in males and in the extremities. Our cohort was too small to provide meaningful statistical analysis; however, we observed lower rates of local recurrence in patients treated with radiation.
背景骨外黏液样软骨肉瘤(EMC)是一种罕见的恶性软组织肉瘤(STS),在所有软组织肿瘤中所占比例不到3%。原发性EMC的传统治疗方法是广泛的局部切除,无论是否进行放射治疗。材料和方法本研究对1992年至2019年间在一家机构接受治疗的所有EMC病例进行了回顾性审查。采用组织形态学和免疫染色相结合的方法,结合荧光原位杂交对EMC进行诊断。总生存期(OS)和疾病特异性生存期(DSS)采用Kaplan-Meier分析进行定义。结果15例患者接受了评估,其中男性11例,女性4例。出现时的平均年龄为51.7±20.4岁,平均随访时间为61.5个月(范围为5-286个月)。最大尺寸的平均切除肿瘤大小为7.14cm(范围2.4-18.7)。15名患者中有12名(80%)接受了广泛的局部切除,12名患者中的9名(75%)接受了局部放射治疗。1年、5年和10年OS分别为80%(95%CI,59.8-100)、72%(95%CI,48.5-95.5)和72%(95%可信区间,48.5-9.5)。1年、5年和10年DSS分别为92.3%(95%置信区间,77.8-100)、83.1%(95%可信区间,61.5-100)和83.1%(95%CI,61.5-100)。在最后的随访中,11名患者存活,10名(90.9%)无疾病。结论骨外黏液样软骨肉瘤是一种非常罕见的STS,最常见于男性和四肢。我们的队列太小,无法提供有意义的统计分析;然而,我们观察到接受放射治疗的患者局部复发率较低。
{"title":"Extraskeletal myxoid chondrosarcoma: A case series and review of the literature","authors":"Michael P. Fice, Linus Lee, Pavan Kottamasu, Abdullah Almajnooni, Matthew R. Cohn, Charles A. Gusho, S. Gitelis, Alan T. Blank","doi":"10.1177/20363613221079754","DOIUrl":"https://doi.org/10.1177/20363613221079754","url":null,"abstract":"Background Extraskeletal myxoid chondrosarcoma (EMC) is a rare malignant soft tissue sarcoma (STS) that accounts for less than 3% of all soft tissue tumors. The conventional treatment for primary EMC is wide local excision with or without radiation therapy. Materials and Methods This study was a retrospective review of all EMC cases treated within a single institution between 1992 and 2019. EMC was diagnosed using a combination of histologic morphology and immunostaining, with confirmatory fluorescent in situ hybridization. Overall survival (OS) and disease-specific survival (DSS) were defined using Kaplan–Meier analysis. Results Fifteen patients were evaluated, including 11 males and four females. The average age at presentation was 51.7 ± 20.4 years and the mean follow-up time was 61.5 months (range, 5–286 months). The average resected tumor size at largest dimension was 7.14 cm (range, 2.4–18.7). Twelve of fifteen (80%) patients underwent wide local excision, and nine of the twelve (75%) underwent local radiation therapy. The 1-, 5-, and 10-year OS was 80% (95% CI, 59.8–100), 72% (95% CI, 48.5–95.5), and 72% (95% CI, 48.5–95.5), respectively. The 1-, 5-, and 10-year DSS was 92.3% (95% CI, 77.8–100), 83.1% (95% CI, 61.5–100), and 83.1% (95% CI, 61.5–100), respectively. At last follow-up, 11 patients were alive and ten (90.9%) were disease free. Conclusions Extraskeletal myxoid chondrosarcoma is a very rare STS most often seen in males and in the extremities. Our cohort was too small to provide meaningful statistical analysis; however, we observed lower rates of local recurrence in patients treated with radiation.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43245665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Pelvic retroperitoneal pleomorphic hyalinizing angiectatic tumor: A case report and review of literature. 盆腔腹膜后多形性透明化血管扩张瘤1例并文献复习。
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221103751
Mehdi Salehipour, Mohammad Hossein Anbardar, Bita Geramizadeh, Hamed Jafari, Ali Zare, Ali Adib

Pleomorphic hyalinizing angiectatic tumor (PHAT) is a rare tumor of the soft tissue, usually located in lower extremities. There are rarely tumors reported in other anatomic locations. Herein, we report retroperitoneal PHAT in a male patient. A 41-year-old man was referred to our clinic due to an incidentally found retroperitoneal mass. Computed tomography (CT) scan showed a solid hypoechoic lesion containing fat component and calcified elements measuring about 80*72*45 mm in the right lower quadrant (RLQ) of the abdomen. Magnetic resonance imaging (MRI) showed circumscribe lesion measuring about 60 x 48 mm with partial enhancement and fat component. In pelvic exploration, a large mass was found that had encased the right external iliac artery and vein. Therefore, the mass and its surrounding iliac vessels were excised and removed en block. Then, the external iliac vessels were reconstructed with Gortex graft. No recurrence was found in 1 month and 3 months post-operation follow up. We report a pelvic retroperitoneal PHAT as a rare location of this tumor. It seems that PHAT must be considered in differential diagnosis in patients with soft tissue tumors in the pelvic cavity.

摘要多形性透明化血管扩张瘤(PHAT)是一种罕见的软组织肿瘤,通常位于下肢。在其他解剖部位很少有肿瘤的报道。在此,我们报告一位男性患者腹膜后PHAT。一位41岁的男性因偶然发现腹膜后肿块而被转介到我们诊所。CT示腹部右下象限(RLQ)一实性低回声病灶,含脂肪成分和钙化元素,大小约80*72*45 mm。磁共振成像(MRI)显示病灶范围约60 x 48 mm,局部增强,脂肪成分。在盆腔探查中,发现一个大肿块包裹了右侧髂外动脉和静脉。因此,肿块及其周围的髂血管被切除并整体切除。然后用Gortex移植物重建髂外血管。术后1个月及3个月随访均无复发。我们报告盆腔腹膜后PHAT是一个罕见的肿瘤位置。因此,在盆腔软组织肿瘤患者的鉴别诊断中必须考虑到PHAT。
{"title":"Pelvic retroperitoneal pleomorphic hyalinizing angiectatic tumor: A case report and review of literature.","authors":"Mehdi Salehipour,&nbsp;Mohammad Hossein Anbardar,&nbsp;Bita Geramizadeh,&nbsp;Hamed Jafari,&nbsp;Ali Zare,&nbsp;Ali Adib","doi":"10.1177/20363613221103751","DOIUrl":"https://doi.org/10.1177/20363613221103751","url":null,"abstract":"<p><p>Pleomorphic hyalinizing angiectatic tumor (PHAT) is a rare tumor of the soft tissue, usually located in lower extremities. There are rarely tumors reported in other anatomic locations. Herein, we report retroperitoneal PHAT in a male patient. A 41-year-old man was referred to our clinic due to an incidentally found retroperitoneal mass. Computed tomography (CT) scan showed a solid hypoechoic lesion containing fat component and calcified elements measuring about 80*72*45 mm in the right lower quadrant (RLQ) of the abdomen. Magnetic resonance imaging (MRI) showed circumscribe lesion measuring about 60 x 48 mm with partial enhancement and fat component. In pelvic exploration, a large mass was found that had encased the right external iliac artery and vein. Therefore, the mass and its surrounding iliac vessels were excised and removed en block. Then, the external iliac vessels were reconstructed with Gortex graft. No recurrence was found in 1 month and 3 months post-operation follow up. We report a pelvic retroperitoneal PHAT as a rare location of this tumor. It seems that PHAT must be considered in differential diagnosis in patients with soft tissue tumors in the pelvic cavity.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/51/60/10.1177_20363613221103751.PMC9150221.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10252651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary leiomyosarcoma of the colon with synchronous liver metastasis 原发性结肠平滑肌肉瘤伴同步肝转移
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221080549
D. Massaras, E. Kontis, K. Stamatis, E. Zampeli, D. Myoteri, Elias Primetis, E. Pantiora, G. Fragulidis
Leiomyosarcomas (LMS) are mesenchymal tumors of smooth muscle origin. Approximately 20% of leiomyosarcomas are found in the GI tract, and account for 1–2% of GI malignancies. Within the gastrointestinal tract, the small intestine is the most common site of presentation followed by the colon. They are often diagnosed incidentally during abdominal pain investigation, and they usually present in the fifth decade of life. In the past, the diagnostic differentiation between leiomyosarcomas of gastrointestinal tract and gastrointestinal stromal tumors (GISTs) was very challenging as they share common microscopic appearance. Nowadays, these tumors are diagnosed by immunohistochemical methods as they are positive for smooth muscle markers actin (SMA) and desmin, negative for GIST markers such as receptor tyrosine kinase (KIT), CD34, DOG1, and negative for the schwannoma marker S100 protein. In the current literature, most cases of intestinal leiomyosarcomas are localized in the small intestine, and there are no reports of synchronous liver metastases at the time of presentation of the primary tumor. Herein, we present a patient who was admitted in our department, with the diagnosis of primary leiomyosarcoma of the colon and synchronous liver metastasis.
平滑肌肉瘤(LMS)是起源于平滑肌的间质肿瘤。大约20%的平滑肌肉瘤发生在胃肠道,占胃肠道恶性肿瘤的1-2%。在胃肠道内,小肠是最常见的发病部位,其次是结肠。通常是在腹痛调查中偶然发现的,通常出现在50岁左右。由于胃肠道平滑肌肉瘤与胃肠道间质瘤(gist)在显微镜下具有相同的外观,因此过去的诊断鉴别非常具有挑战性。目前,这些肿瘤通过免疫组织化学方法诊断,因为它们的平滑肌标志物肌动蛋白(SMA)和desmin呈阳性,GIST标志物如受体酪氨酸激酶(KIT)、CD34、DOG1呈阴性,神经鞘瘤标志物S100蛋白呈阴性。在目前的文献中,大多数肠道平滑肌肉瘤的病例局限于小肠,在原发肿瘤出现时没有同步肝转移的报道。在此,我们报告一位在我科住院的病人,诊断为原发性结肠平滑肌肉瘤并同步肝转移。
{"title":"Primary leiomyosarcoma of the colon with synchronous liver metastasis","authors":"D. Massaras, E. Kontis, K. Stamatis, E. Zampeli, D. Myoteri, Elias Primetis, E. Pantiora, G. Fragulidis","doi":"10.1177/20363613221080549","DOIUrl":"https://doi.org/10.1177/20363613221080549","url":null,"abstract":"Leiomyosarcomas (LMS) are mesenchymal tumors of smooth muscle origin. Approximately 20% of leiomyosarcomas are found in the GI tract, and account for 1–2% of GI malignancies. Within the gastrointestinal tract, the small intestine is the most common site of presentation followed by the colon. They are often diagnosed incidentally during abdominal pain investigation, and they usually present in the fifth decade of life. In the past, the diagnostic differentiation between leiomyosarcomas of gastrointestinal tract and gastrointestinal stromal tumors (GISTs) was very challenging as they share common microscopic appearance. Nowadays, these tumors are diagnosed by immunohistochemical methods as they are positive for smooth muscle markers actin (SMA) and desmin, negative for GIST markers such as receptor tyrosine kinase (KIT), CD34, DOG1, and negative for the schwannoma marker S100 protein. In the current literature, most cases of intestinal leiomyosarcomas are localized in the small intestine, and there are no reports of synchronous liver metastases at the time of presentation of the primary tumor. Herein, we present a patient who was admitted in our department, with the diagnosis of primary leiomyosarcoma of the colon and synchronous liver metastasis.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48957682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Giant teratoma of the pancreas expanding to the mediastinum: Rare tumor and literature review. 胰腺巨大畸胎瘤扩散至纵隔:罕见肿瘤及文献回顾。
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221147470
Nikolaos Tasis, Antonia A Prountzopoulou, Evangelia Skafida, Maria Arnaouti, Theodoros Tsirlis, Aris Plastiras, Dimitrios K Manatakis, Niki Arnogiannaki, Dimitrios P Korkolis

Pancreatic mature cystic teratomas are very rare with limited cases found in the literature. These lesions raise a diagnostic challenge and complicate the surgical approach not only because of their anatomic position but also because of their ever-growing size. An elusive diagnosis, usually leads to the operative theatre where surgical resection takes place. We present a rare case of a large pancreatic cystic teratoma extending into the mediastinum in a 29-year-old woman which was succesfully managed with en-bloc distal pancreatectomy and spleenectomy.

胰腺成熟囊性畸胎瘤是非常罕见的,在文献中发现的病例有限。这些病变不仅由于其解剖位置,而且由于其不断增长的大小,对诊断提出了挑战,并使手术入路复杂化。一个难以捉摸的诊断,通常导致手术切除进行手术室。我们报告一个罕见的病例,一个巨大的胰腺囊性畸胎瘤延伸到纵隔,在一个29岁的女性成功地管理与整体远端胰腺切除术和脾切除术。
{"title":"Giant teratoma of the pancreas expanding to the mediastinum: Rare tumor and literature review.","authors":"Nikolaos Tasis,&nbsp;Antonia A Prountzopoulou,&nbsp;Evangelia Skafida,&nbsp;Maria Arnaouti,&nbsp;Theodoros Tsirlis,&nbsp;Aris Plastiras,&nbsp;Dimitrios K Manatakis,&nbsp;Niki Arnogiannaki,&nbsp;Dimitrios P Korkolis","doi":"10.1177/20363613221147470","DOIUrl":"https://doi.org/10.1177/20363613221147470","url":null,"abstract":"<p><p>Pancreatic mature cystic teratomas are very rare with limited cases found in the literature. These lesions raise a diagnostic challenge and complicate the surgical approach not only because of their anatomic position but also because of their ever-growing size. An elusive diagnosis, usually leads to the operative theatre where surgical resection takes place. We present a rare case of a large pancreatic cystic teratoma extending into the mediastinum in a 29-year-old woman which was succesfully managed with en-bloc distal pancreatectomy and spleenectomy.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/bb/10.1177_20363613221147470.PMC9806373.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10494337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A rare case report of a myxoid liposarcoma arising from the broad ligament. 摘要一例发生于阔韧带的黏液样脂肪肉瘤。
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221148839
Farah Sassi, Ghada Sahraoui, Lamia Charfi, Zemni Ines, Karima Mrad, Raoudha Doghri

Myxoid liposarcoma (MLPS) is the second most prevalent subtype of liposarcoma. It is usually found in the deep tissues of the lower limbs and rarely in gynecologic tract. Herein we present the second case in the English literature of a primary MLPS arising from the broad ligament which was thought to be a borderline ovarian tumor. The aim is to discuss its clinical and pathological characteristics. A 42-year-old woman presented with pelvic pain for the last 6 months. Magnetic resonance imaging was not specific. She underwent a surgical resection of the tumor mass, and pathological examination confirmed the diagnosis of MLPS deriving from the broad ligament. She received radiotherapy and the patient is doing well at 3 months follow-up. The clinical aspects, pathological diagnosis, prognosis, and therapy approach of broad ligament MLPS are all poorly understood. Complete surgical resection with or without radiotherapy is the mainstay of treatment in located MLPS.

黏液样脂肪肉瘤(MLPS)是第二常见的脂肪肉瘤亚型。它通常发生在下肢深部组织,很少发生在妇科。在这里,我们提出了第二个病例在英文文献中原发性MLPS起源于宽韧带,这被认为是一个边缘性卵巢肿瘤。目的是探讨其临床和病理特点。一名42岁女性,过去6个月出现骨盆疼痛。磁共振成像不明确。她接受手术切除肿瘤肿块,病理检查证实诊断为起源于阔韧带的MLPS。患者接受放射治疗,随访3个月,恢复良好。目前对宽韧带MLPS的临床、病理诊断、预后及治疗方法都知之甚少。完全手术切除加或不加放疗是定位性MLPS的主要治疗方法。
{"title":"A rare case report of a myxoid liposarcoma arising from the broad ligament.","authors":"Farah Sassi,&nbsp;Ghada Sahraoui,&nbsp;Lamia Charfi,&nbsp;Zemni Ines,&nbsp;Karima Mrad,&nbsp;Raoudha Doghri","doi":"10.1177/20363613221148839","DOIUrl":"https://doi.org/10.1177/20363613221148839","url":null,"abstract":"<p><p>Myxoid liposarcoma (MLPS) is the second most prevalent subtype of liposarcoma. It is usually found in the deep tissues of the lower limbs and rarely in gynecologic tract. Herein we present the second case in the English literature of a primary MLPS arising from the broad ligament which was thought to be a borderline ovarian tumor. The aim is to discuss its clinical and pathological characteristics. A 42-year-old woman presented with pelvic pain for the last 6 months. Magnetic resonance imaging was not specific. She underwent a surgical resection of the tumor mass, and pathological examination confirmed the diagnosis of MLPS deriving from the broad ligament. She received radiotherapy and the patient is doing well at 3 months follow-up. The clinical aspects, pathological diagnosis, prognosis, and therapy approach of broad ligament MLPS are all poorly understood. Complete surgical resection with or without radiotherapy is the mainstay of treatment in located MLPS.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4b/05/10.1177_20363613221148839.PMC9793064.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10446283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
EXPRESSION OF CONCERN: The first case report of primary thyroid teratocarcinosarcoma: An analog to sinonasal teratocarcinosarcoma 关注的表达:第一例原发性甲状腺畸胎癌肉瘤:一种类似于鼻腔畸胎癌的肉瘤
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221101702
[This corrects the article DOI: 10.1177/20363613211043662.].
[这更正了文章DOI:10.1177/2036363132103662.]。
{"title":"EXPRESSION OF CONCERN: The first case report of primary thyroid teratocarcinosarcoma: An analog to sinonasal teratocarcinosarcoma","authors":"","doi":"10.1177/20363613221101702","DOIUrl":"https://doi.org/10.1177/20363613221101702","url":null,"abstract":"[This corrects the article DOI: 10.1177/20363613211043662.].","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42188294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and paraclinical features, outcome, and prognosis of ovarian granulosa cell tumor: A retrospective study of 28 Vietnamese women. 卵巢颗粒细胞瘤的临床和临床特征、结局和预后:对28名越南妇女的回顾性研究。
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221148547
Duc Thanh Le, Tu Anh Do, Linh Ly Thi Nguyen, Kien Hung Do, Chu Van Nguyen

Background: Granulosa cell tumor of the ovary is a rare disease and presents with two clinically and molecularly distinct subtypes: the juvenile and the adult type. GCT is considered as a malignant tumor with an indolent course and a tendency toward late recurrence. Purpose: To assess the clinical and paraclinical features, treatment findings, survival outcomes, and explored the prognostic factors in the granulosa cell tumor. Methods: The current study was conducted on 28 GCT patients who had surgical operations and adjuvant chemotherapy (stage IC-IV) by applying a retrospective cohort analysis. The clinical and paraclinical characteristics were recorded. Recurrent status was evaluated for analysis with clinical and paraclinical features and survival. All GCT patients' survival were analyzed by using Kaplan-Meier and Log-Rank models. Results: 17.9% of patients experienced a relapse and two patients died due to disease. The mean time from initial diagnose to recurrence was 40.21 months. The 5-year OS and DFS of stage I-II were 100% and 80.8%, and of stage III were 50% and 25%, respectively. In survival analyses, using the log-rank test, age ≥50 years, irregular menstruation, stage I-II, and absence of residual lesion were all significant predictors for the improved DFS. Stage I-II and absence of residual lesion were associated significantly with better OS. Mean of age, FIGO stage, and residual lesion during surgery had significant differences to recurrent rate (p < <0.05). The multivariate model revealed that these factors didn't remain as an independent prognostic variable. Conclusion: FIGO stage and residual lesion during surgery had significant differences in survival and recurrent rate.

背景:卵巢颗粒细胞瘤是一种罕见的疾病,临床表现为两种不同的亚型:少年型和成年型。GCT被认为是一种恶性肿瘤,病程缓慢,有晚期复发的倾向。目的:评价颗粒细胞瘤的临床及临床旁特征、治疗结果、生存结局,探讨影响预后的因素。方法:本研究采用回顾性队列分析方法,对28例接受外科手术和辅助化疗(IC-IV期)的GCT患者进行研究。记录临床及临床旁特征。评估复发情况,分析临床和临床外特征及生存率。采用Kaplan-Meier和Log-Rank模型分析所有GCT患者的生存情况。结果:17.9%的患者复发,2例因病死亡。从初诊到复发的平均时间为40.21个月。I-II期5年OS和DFS分别为100%和80.8%,III期为50%和25%。在生存分析中,使用log-rank检验,年龄≥50岁、月经不调、I-II期和无残留病变都是改善DFS的重要预测因素。I-II期和无残留病变与较好的OS显著相关。平均年龄、FIGO分期、术中残余病变与复发率差异有统计学意义(p < 0.05)。结论:FIGO分期、术中残余病变在生存率和复发率上有统计学意义。
{"title":"Clinical and paraclinical features, outcome, and prognosis of ovarian granulosa cell tumor: A retrospective study of 28 Vietnamese women.","authors":"Duc Thanh Le,&nbsp;Tu Anh Do,&nbsp;Linh Ly Thi Nguyen,&nbsp;Kien Hung Do,&nbsp;Chu Van Nguyen","doi":"10.1177/20363613221148547","DOIUrl":"https://doi.org/10.1177/20363613221148547","url":null,"abstract":"<p><p><b>Background:</b> Granulosa cell tumor of the ovary is a rare disease and presents with two clinically and molecularly distinct subtypes: the juvenile and the adult type. GCT is considered as a malignant tumor with an indolent course and a tendency toward late recurrence. <b>Purpose</b>: To assess the clinical and paraclinical features, treatment findings, survival outcomes, and explored the prognostic factors in the granulosa cell tumor. <b>Methods</b>: The current study was conducted on 28 GCT patients who had surgical operations and adjuvant chemotherapy (stage IC-IV) by applying a retrospective cohort analysis. The clinical and paraclinical characteristics were recorded. Recurrent status was evaluated for analysis with clinical and paraclinical features and survival. All GCT patients' survival were analyzed by using Kaplan-Meier and Log-Rank models. <b>Results</b>: 17.9% of patients experienced a relapse and two patients died due to disease. The mean time from initial diagnose to recurrence was 40.21 months. The 5-year OS and DFS of stage I-II were 100% and 80.8%, and of stage III were 50% and 25%, respectively. In survival analyses, using the log-rank test, age ≥50 years, irregular menstruation, stage I-II, and absence of residual lesion were all significant predictors for the improved DFS. Stage I-II and absence of residual lesion were associated significantly with better OS. Mean of age, FIGO stage, and residual lesion during surgery had significant differences to recurrent rate (p < <0.05). The multivariate model revealed that these factors didn't remain as an independent prognostic variable. <b>Conclusion</b>: FIGO stage and residual lesion during surgery had significant differences in survival and recurrent rate.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/12/10.1177_20363613221148547.PMC9793063.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10455193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Title: Clinico-pathological and survival profiles of orbito-ocular tumors in Enugu Nigeria. Is there an emerging trend? 标题:尼日利亚埃努古眼眶肿瘤的临床病理和生存情况。是否有新的趋势?
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221079763
N. Uche, O. Okoye, O. Okoye, I. Oguegbu, E. Uche
Background Orbito-ocular tumors are rare, but they cause significant morbidity and mortality. There are reported variations in their pattern of presentation and frequency of occurrence. Objective To evaluate the occurrence, clinico-pathologic spectrum, and patterns of orbito-ocular neoplasms as well as the treatment and outcome profiles. Methods A 5-year retrospective analysis of consecutive patients treated for orbito-ocular tumors. We evaluated patterns of occurrence, clinic-pathological concordance, and outcome of treatment. Associations were evaluated with chi square and confidence interval. Data analysis was performed using SPSS for windows version 23 and inferences were judged using the 95% level of significance. Results Among 100 patients with orbito-ocular masses, 62 were histologically confirmed. The female to male ratio (F:M) was 1.0. Their ages ranged from 7 months to 93 years, mean = 33.4 ± 2.7 years. There was an age variation among tumor types. Patients with squamous cell carcinoma (SCC) had a mean age of 46.4 years, while for retinoblastoma the mean age was 3.09 years. All patients with retinoblastoma had proven macroscopic orbital extension. SCC was the most common tumor type (n = 19), however, among children, retinoblastoma (n = 11) was more common. Melanocytic nevus, sebaceous gland carcinoma, and adenocarcinoma of lacrimal gland (n = 6, n = 5, n = 5), respectively, among other tumors were treated. Concordance between clinical and histopathological diagnoses was obtained among 30 (48.3%) cases. 1-year and 3-year survival for retinoblastoma was 90% and 72.9%, respectively, and 78.9% and 68.4% for SCC. Conclusion SCC is currently the most common orbito-ocular tumor in our setting.
背景眼眶肿瘤是罕见的,但它们会导致严重的发病率和死亡率。据报道,它们的表现模式和发生频率各不相同。目的评价眼眶肿瘤的发生、临床病理谱、类型、治疗方法和疗效。方法对连续5年接受眼眶肿瘤治疗的患者进行回顾性分析。我们评估了发病模式、临床病理一致性和治疗结果。相关性用卡方和置信区间进行评估。使用SPSS for windows 23版进行数据分析,并使用95%的显著性水平判断推断。结果在100例眼眶肿块患者中,62例经组织学证实。男女比例(F:M)为1.0。年龄7个月~93岁,平均33.4±2.7岁。肿瘤类型之间存在年龄差异。鳞状细胞癌(SCC)患者的平均年龄为46.4岁,而视网膜母细胞瘤的平均年龄是3.09岁。所有视网膜母细胞瘤患者均已证实肉眼可见眼眶扩张。SCC是最常见的肿瘤类型(n=19),然而,在儿童中,视网膜母细胞瘤(n=11)更常见。除其他肿瘤外,还分别治疗了黑色素痣、皮脂腺癌和泪腺腺癌(n=6,n=5,n=5)。30例(48.3%)患者的临床诊断与组织病理学诊断符合。视网膜母细胞瘤的1年和3年生存率分别为90%和72.9%,SCC为78.9%和68.4%。结论SCC是目前我们环境中最常见的眼眶肿瘤。
{"title":"Title: Clinico-pathological and survival profiles of orbito-ocular tumors in Enugu Nigeria. Is there an emerging trend?","authors":"N. Uche, O. Okoye, O. Okoye, I. Oguegbu, E. Uche","doi":"10.1177/20363613221079763","DOIUrl":"https://doi.org/10.1177/20363613221079763","url":null,"abstract":"Background Orbito-ocular tumors are rare, but they cause significant morbidity and mortality. There are reported variations in their pattern of presentation and frequency of occurrence. Objective To evaluate the occurrence, clinico-pathologic spectrum, and patterns of orbito-ocular neoplasms as well as the treatment and outcome profiles. Methods A 5-year retrospective analysis of consecutive patients treated for orbito-ocular tumors. We evaluated patterns of occurrence, clinic-pathological concordance, and outcome of treatment. Associations were evaluated with chi square and confidence interval. Data analysis was performed using SPSS for windows version 23 and inferences were judged using the 95% level of significance. Results Among 100 patients with orbito-ocular masses, 62 were histologically confirmed. The female to male ratio (F:M) was 1.0. Their ages ranged from 7 months to 93 years, mean = 33.4 ± 2.7 years. There was an age variation among tumor types. Patients with squamous cell carcinoma (SCC) had a mean age of 46.4 years, while for retinoblastoma the mean age was 3.09 years. All patients with retinoblastoma had proven macroscopic orbital extension. SCC was the most common tumor type (n = 19), however, among children, retinoblastoma (n = 11) was more common. Melanocytic nevus, sebaceous gland carcinoma, and adenocarcinoma of lacrimal gland (n = 6, n = 5, n = 5), respectively, among other tumors were treated. Concordance between clinical and histopathological diagnoses was obtained among 30 (48.3%) cases. 1-year and 3-year survival for retinoblastoma was 90% and 72.9%, respectively, and 78.9% and 68.4% for SCC. Conclusion SCC is currently the most common orbito-ocular tumor in our setting.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43326354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial 多柔比星治疗软组织肉瘤患者在ANNOUNCE III期临床试验中的生活质量
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221100033
B. V. Van Tine, A. Krarup-Hansen, L. Hess, A. A. Abdul Razak, V. Soldatenkova, Jennifer Wright, S. Park
Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported from patients with advanced or metastatic soft tissue sarcoma (STS) enrolled to the ANNOUNCE phase III trial of doxorubicin-based therapy. Methods: ANNOUNCE was a phase III trial that randomized 509 patients with STS to receive up to eight cycles of doxorubicin with olaratumab or placebo, followed by single-agent olaratumab or placebo. Dexrazoxane was allowed at any cycle of treatment. Participants completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30, which is scored 0–100), and Brief Pain Inventory Short Form Modified (mBPI-sf, scored from 0–10) at each treatment cycle. A descriptive analysis of the longitudinal data was conducted overall and by cumulative dose of doxorubicin received to inform the clinical care of patients with STS. Worsening on the QLQ-C30 was defined as a change of 10 points or more at any post-baseline assessment. Worsening on the mPBI-sf was defined as an increase of ≥2 points from baseline. Results: The majority of participants completed the baseline and at least one subsequent PRO assessment within the trial (n = 460, 90.4% EORTC QLQ-C30; n = 454, 89.2%, mBPI-sf). Patients with STS enrolled to the ANNOUNCE trial had clinically meaningful problems with physical function and pain before initiating doxorubicin. Overall, those with fewer symptoms or better function at baseline received higher cumulative doxorubicin dose throughout the study. At baseline, mean QLQ-C30 fatigue was 29.9 with a median time to first worsening of 0.9 months, and mean nausea/vomiting was 6.5 with 1.4 months until worsening; mean physical function was 78.3 with median time to worsening of 2.1 months and mean health status was 66.8 with median time to first worsening of 1.6 months. Median time to worsening of pain was 7.9 months. Conclusion: Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. The availability of detailed summary data from the patient perspective during doxorubicin-based treatment may inform future care of these patients and can provide a resource for the development of PRO endpoints in future trials.
背景:建议在临床试验中常规收集患者报告的结局(PROs),包括与健康相关的生活质量,但肉瘤患者试验的数据有限。在这项分析中,汇总的PRO数据来自于参加了基于阿霉素的治疗的ANNOUNCE III期试验的晚期或转移性软组织肉瘤(STS)患者。方法:ANNOUNCE是一项III期试验,随机分配509名STS患者接受最多8个周期的阿霉素联合奥拉拉单抗或安慰剂治疗,随后接受单药奥拉拉单抗或安慰剂治疗。在任何治疗周期都允许使用右唑嗪。参与者在每个治疗周期完成欧洲癌症研究和治疗组织生活质量问卷-核心30 (EORTC QLQ-C30,评分为0-100)和简短疼痛量表短表修改(mBPI-sf,评分为0-10)。对纵向数据进行描述性分析,并通过接受阿霉素的累积剂量,为STS患者的临床护理提供信息。QLQ-C30的恶化被定义为在任何基线后评估中变化10分或更多。mPBI-sf恶化定义为较基线增加≥2点。结果:大多数参与者在试验期间完成了基线和至少一次后续PRO评估(n = 460, 90.4% EORTC QLQ-C30;n = 454, 89.2%, mBPI-sf)。参加ANNOUNCE试验的STS患者在开始使用阿霉素之前,存在有临床意义的身体功能和疼痛问题。总的来说,那些在基线时症状较少或功能较好的患者在整个研究过程中接受了较高的累积阿霉素剂量。基线时,QLQ-C30疲劳平均为29.9分,至首次恶化的中位时间为0.9个月;恶心/呕吐平均为6.5分,至恶化的平均时间为1.4个月;平均身体机能为78.3,中位恶化时间为2.1个月;平均健康状况为66.8,中位首次恶化时间为1.6个月。疼痛恶化的中位时间为7.9个月。结论:晚期或转移性肉瘤患者报告说,在以阿霉素为基础的治疗期间,PROs下降相对迅速,患者在基线时症状较差(特别是疲劳),随后接受较少的阿霉素治疗。在阿霉素治疗期间,从患者角度获得详细的汇总数据,可以为这些患者的未来护理提供信息,并可以为未来试验中PRO终点的开发提供资源。
{"title":"Quality of life of patients with soft tissue sarcoma treated with doxorubicin in the ANNOUNCE phase III clinical trial","authors":"B. V. Van Tine, A. Krarup-Hansen, L. Hess, A. A. Abdul Razak, V. Soldatenkova, Jennifer Wright, S. Park","doi":"10.1177/20363613221100033","DOIUrl":"https://doi.org/10.1177/20363613221100033","url":null,"abstract":"Background: Patient-reported outcomes (PROs), including health-related quality of life, are recommended to be routinely collected in clinical trials, but data are limited from trials of sarcoma patients. In this analysis, pooled PRO data are reported from patients with advanced or metastatic soft tissue sarcoma (STS) enrolled to the ANNOUNCE phase III trial of doxorubicin-based therapy. Methods: ANNOUNCE was a phase III trial that randomized 509 patients with STS to receive up to eight cycles of doxorubicin with olaratumab or placebo, followed by single-agent olaratumab or placebo. Dexrazoxane was allowed at any cycle of treatment. Participants completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30, which is scored 0–100), and Brief Pain Inventory Short Form Modified (mBPI-sf, scored from 0–10) at each treatment cycle. A descriptive analysis of the longitudinal data was conducted overall and by cumulative dose of doxorubicin received to inform the clinical care of patients with STS. Worsening on the QLQ-C30 was defined as a change of 10 points or more at any post-baseline assessment. Worsening on the mPBI-sf was defined as an increase of ≥2 points from baseline. Results: The majority of participants completed the baseline and at least one subsequent PRO assessment within the trial (n = 460, 90.4% EORTC QLQ-C30; n = 454, 89.2%, mBPI-sf). Patients with STS enrolled to the ANNOUNCE trial had clinically meaningful problems with physical function and pain before initiating doxorubicin. Overall, those with fewer symptoms or better function at baseline received higher cumulative doxorubicin dose throughout the study. At baseline, mean QLQ-C30 fatigue was 29.9 with a median time to first worsening of 0.9 months, and mean nausea/vomiting was 6.5 with 1.4 months until worsening; mean physical function was 78.3 with median time to worsening of 2.1 months and mean health status was 66.8 with median time to first worsening of 1.6 months. Median time to worsening of pain was 7.9 months. Conclusion: Patients with advanced or metastatic sarcoma reported a relatively rapid decline in PROs during doxorubicin-based treatment, with patients with poorer symptoms at baseline (specifically fatigue), subsequently receiving less doxorubicin therapy. The availability of detailed summary data from the patient perspective during doxorubicin-based treatment may inform future care of these patients and can provide a resource for the development of PRO endpoints in future trials.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47755898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature 青年多形性低级别神经上皮肿瘤:罕见肿瘤及文献复习
IF 0.9 Q4 Medicine Pub Date : 2022-01-01 DOI: 10.1177/20363613221083360
Ali H. Palejwala, Christen M. O’Neal, Michael R Quinton, J. Battiste, J. Peterson, I. Dunn
Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described low-grade neuroepithelial tumor with an infiltrative growth pattern and oligodendrocyte-like cells that are CD34 immunopositive. Correlating histology and results from molecular testing is critical to correctly diagnosing PLNTY, as its histologic appearance is similar to oligodendrogliomas and shares genetic abnormalities common to other low-grade epilepsy associated tumors (LEATs). In this case report, we describe a 31-year-old female with intractable epilepsy found to have a temporal mass and diagnosed with PLNTY after histopathologic and molecular testing. We describe the radiographic, histologic, and genetic features in relation to the epileptic and oncologic outcomes for this patient. Then, we compare these features and outcomes to other cases of PLNTY described in the literature.
多形性青年低级别神经上皮肿瘤(PLNTY)是一种最近描述的低级别神经表皮肿瘤,具有浸润性生长模式和CD34免疫阳性的少突胶质细胞样细胞。相关的组织学和分子检测结果对于正确诊断PLNTY至关重要,因为它的组织学外观与少突胶质瘤相似,并且与其他低度癫痫相关肿瘤(LEAT)有共同的遗传异常。在本病例报告中,我们描述了一名患有顽固性癫痫的31岁女性,经组织病理学和分子检测,发现其颞部有肿块,并被诊断为PLNTY。我们描述了与该患者癫痫和肿瘤学结果相关的放射学、组织学和遗传学特征。然后,我们将这些特征和结果与文献中描述的PLNTY的其他病例进行比较。
{"title":"Polymorphous low-grade neuroepithelial tumor of the young: Rare tumor and review of the literature","authors":"Ali H. Palejwala, Christen M. O’Neal, Michael R Quinton, J. Battiste, J. Peterson, I. Dunn","doi":"10.1177/20363613221083360","DOIUrl":"https://doi.org/10.1177/20363613221083360","url":null,"abstract":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY) is a recently described low-grade neuroepithelial tumor with an infiltrative growth pattern and oligodendrocyte-like cells that are CD34 immunopositive. Correlating histology and results from molecular testing is critical to correctly diagnosing PLNTY, as its histologic appearance is similar to oligodendrogliomas and shares genetic abnormalities common to other low-grade epilepsy associated tumors (LEATs). In this case report, we describe a 31-year-old female with intractable epilepsy found to have a temporal mass and diagnosed with PLNTY after histopathologic and molecular testing. We describe the radiographic, histologic, and genetic features in relation to the epileptic and oncologic outcomes for this patient. Then, we compare these features and outcomes to other cases of PLNTY described in the literature.","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":null,"pages":null},"PeriodicalIF":0.9,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43570520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Rare Tumors
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1